Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368694 | 0.85 | JAK2 (0.40) | JAK2JAK1JAK3MAPK1DGAT1 | |
| SCHEMBL2379249 | 0.84 | CNR2 (0.36) | JAK2JAK1JAK3CNR2DGAT1 | |
| SCHEMBL2379093 | 0.84 | JAK2 (0.45) | JAK2JAK1JAK3CNR2DGAT1 | |
| SCHEMBL2379097 | 0.84 | JAK2 (0.45) | JAK2JAK1JAK3CNR2DGAT1 | |
| SCHEMBL1352318 | 0.80 | MAPT (0.42) | JAK2JAK1JAK3MAPK1DGAT1 | |
| SCHEMBL1371233 | 0.79 | DGAT1 (0.37) | JAK2JAK1JAK3MAPK1DGAT1 | |
| SCHEMBL2378085 | 0.78 | JAK3 (0.62) | JAK2JAK1JAK3MAPK1TYK2 | |
| SCHEMBL12332949 | 0.78 | JAK3 (0.62) | JAK2JAK1JAK3MAPK1TYK2 | |
| SCHEMBL14751009 | 0.77 | CNR2 (0.34) | JAK2JAK1JAK3CNR2DGAT1 | |
| SCHEMBL12333133 | 0.77 | ATR (0.38) | JAK2JAK1JAK3MAPK1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | JAK2 5/4885JAK1 6/4885JAK3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.